Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00408590

NCT00408590
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You must be 18 years of age or older.
  • You must have ovarian cancer or primary peritoneal cancer that has come back, continued to grow, or not gone away after being treated with platinum-based and taxol-based chemotherapy.
  • Your cancer must have been confirmed by a tissue sample (biopsy) of the original tumor, and you must have had both ovaries removed.
  • Your cancer must be one of these specific types: serous, endometroid, mucinous, undifferentiated, clear cell, mixed epithelial, transitional cell, malignant Brenner's tumor, or adenocarcinoma (confirm with trial site if unsure of your type).
  • Your blood test results taken within 7 days before joining must show that your blood counts and organ function are within acceptable ranges (confirm specific numbers with trial site).
  • You must be willing and able to give your consent to take part in the trial.
  • You must be willing to return to Mayo Clinic Rochester for follow-up visits.
  • Doctors must expect you to live for at least 12 weeks.
  • A blood test must show that you have a certain level of immunity to measles.
  • Your blood must show a normal level of a protein called CEA (unless you are in a specific group within the trial called MV-NIS — confirm with trial site).
  • You must be willing to provide all required blood and tissue samples as the trial needs.
  • You must have disease that can be measured on a scan or physical exam, or be willing to have a keyhole surgical procedure (laparoscopy) to check how treatment is working, if your disease cannot be seen on scans after 6 treatment cycles.
  • A blood test must show your immune system has a sufficient level of certain cells (CD4 cells) — confirm details with trial site.

Who may not be able to join:

  • Your ovarian tumor is a type considered "low malignant potential," a stromal tumor, or a germ cell tumor.
  • There is a standard treatment available to you that could cure your cancer or is very likely to extend your life.
  • This is your first time the cancer has come back and it returned more than 6 months after finishing your first course of chemotherapy.
  • You have a low level of physical functioning that significantly limits your daily activity (confirm with trial site).
  • You have had an active infection within 5 days before joining.
  • You have a history of tuberculosis (TB) or have previously tested positive for TB exposure.
  • You have had another type of cancer in the past 5 years, unless it was a common type of skin cancer or a very early-stage cervical condition.
  • You have received chemotherapy within the past 3 weeks, or immunotherapy or biological therapy within the past 4 weeks before joining.
  • You have had major abdominal surgery involving the bowel within the past 3 weeks (minor procedures for the trial itself may not apply — confirm with trial site).
  • You have ever received any viral or gene therapy treatment.
  • You have not fully recovered from the side effects of previous chemotherapy.
  • You have significant heart problems, including serious heart failure, coronary artery disease with symptoms, or certain irregular heart rhythms.
  • You currently need blood transfusions or blood product support.
  • Your cancer has spread to the brain, or you have a seizure disorder.
  • You are HIV-positive or have any other condition that weakens your immune system.
  • You have had an organ transplant.
  • You have a history of long-term (chronic) hepatitis B or C infection.
  • You are currently receiving other chemotherapy, immunotherapy, radiation therapy, or any other experimental treatment.
  • You are taking any medications that could interfere with this trial (confirm with trial site).
  • The disease inside your abdomen is larger than 8 cm, has spread into the liver itself, or has spread outside the abdominal area.
  • You are taking steroid tablets or injections by mouth or into your veins (inhaled or skin-applied steroids may be acceptable — confirm with trial site).
  • You live with or have regular close contact with a child under 15 months old, or with someone who has a weakened immune system.
  • You are allergic to the measles vaccine or have had a severe reaction to it in the past.
  • You are allergic to iodine (note: this does not refer to reactions to contrast d

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Mayo Clinic
Registry
clinicaltrials_gov
Start date
19 April 2004
Est. completion
1 August 2012

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Dose Limiting Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov